markets

EyePoint Pharmaceuticals Faces Securities Class Action Lawsuit

Summarized from All Financial Services & Investing

A law firm has filed a class action against EyePoint Inc. over alleged securities violations affecting investors from early 2025 through mid-2026.

EyePoint Pharmaceuticals Faces Securities Class Action Lawsuit

New York-based law firm Bronstein Gewirtz & Grossman, LLC has announced a securities class action lawsuit against EyePoint Pharmaceuticals Inc., traded on the Nasdaq under the ticker EYPT, targeting alleged misconduct that may have harmed investors over a period spanning more than a year.

Investors who purchased EYPT securities between March 27, 2025, and August 14, 2026, may be eligible to participate in the lawsuit and potentially recover financial losses. The lead plaintiff deadline for the case is set for January 19, 2027, giving affected shareholders time to assess their eligibility and decide whether to join the action.

Read more Leverage Shares Launches Inverse Anthropic ETFs for Bearish Bets →

The lawsuit seeks to recover damages from the defendants over alleged violations of securities law. While the complaint's specific allegations were not fully detailed in the initial announcement, class action suits of this nature typically center on claims that a company made materially false or misleading statements that affected its stock price and harmed investors who relied on those representations.

Shareholders who believe they suffered losses during the defined class period are encouraged to contact the law firm directly. Participation as a lead plaintiff is not required to share in any potential recovery, though those who wish to serve in that capacity must act before the January 2027 deadline.

Securities class actions can take years to resolve, and outcomes are not guaranteed. Investors are advised to consult with legal counsel to understand their rights and options under the case. Continue reading at All Financial Services & Investing.

Frequently Asked Questions

Q.Who is eligible to join the EyePoint Pharmaceuticals class action lawsuit?

Investors who purchased EYPT securities between March 27, 2025, and August 14, 2026, may be eligible to participate in the class action and potentially recover losses.

Q.What is the deadline to join the EyePoint securities class action as lead plaintiff?

The lead plaintiff deadline for the EyePoint class action lawsuit is January 19, 2027.

Q.What law firm filed the class action against EyePoint Pharmaceuticals?

The class action was announced by Bronstein Gewirtz & Grossman, LLC, a New York-based law firm, which is encouraging affected investors to contact the firm directly.

More in markets →